105 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
at European Society of Cardiology Meeting
Company Continues Investment in String of Pearls Strategy with Five Strategic Transactions
Net Sales Increase 11 … ) validated for review the application for ORENCIA SC.
In August, at the European Society of Cardiology (ESC) meeting in Paris, the Company and its
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Jul 13
Bristol-Myers Squibb Reports Second Quarter 2013 Financial Results
12:00am
thromboembolism, were published online by theNew England Journal of Medicine and presented at the International Society on Thrombosis and Haemostasis … at the European Society of Cardiology meeting in September.
Metreleptin
In June, the FDA accepted the filing and granted a Priority Review designation
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
23 Jul 15
Bristol-Myers Squibb Reports Second Quarter Financial Results
12:00am
and significant clinical data on the company’s Immuno-Oncology portfolio presented at the American Society of Clinical Oncology (ASCO).
“We had a very good … , demonstrated a 28% reduction in the risk of disease progression or death.
Eliquis
In June, at the International Society on Thrombosis and Haemostasis
424B3
BMY
Bristol-Myers Squibb Co.
13 Jul 05
Prospectus supplement
12:00am
MedAmerica New York Insurance
MedAmerica Insurance
Attorney's Liability Assurance Society
Concord Hospital Employee's Pension Fund
Concord Hospital Non
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
22 Oct 09
Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter
12:00am
-aventis announced results of the CURRENT OASIS-7 study at the European Society of Cardiology. The study provided information about an intensified dose … session at the Congress of the International Society of Thrombosis and Hemostasis. The study demonstrated that apixaban was superior to the European
8-K
EX-99.1
8izc 9kik0pigh8
28 Apr 11
Key R&D Milestones and Strong Financials
12:00am
8-K
EX-99.1
j5xnkk dm0fp2x
25 Oct 18
Bristol-Myers Squibb Reports Third Quarter Financial Results
8:02am
8-K
EX-99.1
9becmqo
24 Jan 13
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2012 Financial Results
12:00am
8-K
EX-99.1
xlogn34to o90qz
31 Oct 19
Bristol-Myers Squibb Reports Third Quarter Financial Results
8:01am
8-K
EX-99.1
eeh2 ars9qi
24 Oct 14
Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
tnr3zb068nxou51m
28 Jul 11
Important Clinical Data and Strong Financial Results
12:00am
8-K
EX-99.1
l7nfewwq54i 2uh0ydl
27 Oct 16
Bristol-Myers Squibb Reports Third Quarter Financial Results
12:00am
8-K
EX-99.1
cf0 ou7qv2f
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
anjt4oycojzz0rhq9
27 Jan 15
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results
12:00am
8-K
EX-99.1
s8co28gx k1r9ocuqyix
27 Oct 21
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
9:46am
8-K
EX-99
p99u4wbw
29 Apr 03
Financial statements and exhibits
12:00am
8-K
EX-99.1
cru5zxskqfyf wfhi
26 Jul 18
Bristol-Myers Squibb Reports Second Quarter Financial Results
8:05am
425
5e4f921hc
15 Mar 19
Business combination disclosure
5:23pm
DEF 14A
pty8ri4x2w02r5an wtn
15 Mar 94
Definitive proxy
12:00am
8-K
EX-99.1
7f8rz
25 Jul 12
Planned Acquisition of Amylin Expected to Add Two Marketed GLP-1 Agonists to Our Diabetes Franchise and Our Alliance with AstraZeneca
12:00am